Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals
EPIC: SLN
Latest Price: 168.50  (-0.30% Descending)
52-week High: 312.50
52-week Low: 37.50
Market Cap: 79.22M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Silence Therapeutics
www.silence-therapeutics.com

Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases.

The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercialising RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio.

Full Silence Therapeutics profile here
Pdf

UPDATE: Silence Therapeutics unveils tie-up with one of the world's leading drugs companies

27th Sep 2011, 10:40 am by Ian Lyall

Adds broker comments....

Silence Therapeutics (LON:SLN) has struck a deal with one of the world’s leading global pharmaceuticals companies, which will further its research into short interfering RNA sequences, known as siRNAs.

The two will look at the intravenous use of Silence’s DACC technology to deliver siRNAs to the lung.

The name of the drugs giant involved was not revealed. The biotechnology group already has tie-ups with Pfizer (NYSE:PFE), Novartis (VTX:NOVN) and AstraZeneca (LON:AZN).

At the very leading edge of drug development, siRNAs are double-stranded molecules that silence certain genes. They are being developed to be used in targeting multiple disease types, including cancer.

Newly appointed chief executive Thomas Christély said of this latest alliance: "We are delighted to be collaborating with another of the world's largest  pharmaceutical companies for the use of our delivery systems to deliver their selected siRNAs.

“As we have stated, Silence is now significantly increasing its  resource in business development, and we are delighted to be announcing another  partnership.

“We believe that Silence's proprietary DACC delivery system offers  the potential to selectively deliver siRNAs and other oligonucleotides to pulmonary vascular endothelium, and we look forward to working closely with our  partner on this project.

“Functional delivery into target cells is one of the greatest challenges facing most nucleic acid therapies and Silence remains  committed to the development of its DACC and its other proprietary delivery  systems, including AtuPLEXtm and DBTC, as it seeks to overcome these challenges."

Analyst Shawn Manning, at broker Singer, said today's announcement was not "entirely unexpected" because of the firm's unique delivery system and the unmet need for a reliable delivery system for siRNA.

"However, the deal further validates Silence’s approach, and although the partnership is likely to be 12-18 months away from generation of a lead candidate, the agreement demonstrates that Silence’s technology platform remains in demand," he said, adding that the broker maintained its positive outlook for the company.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here